Clinical Trial Update: Safety of and Immune Response to a Dengue Virus Vaccine (rDEN2/4delta30[ME]) in Healthy Adults [Phase 1]

View source ↗

Summary

Phase 1 trial assessing the safety and immune response of the dengue vaccine candidate rDEN2/4delta30[ME] in healthy adults.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dengue Fever

Drugs mentioned

• rDEN2/4delta30[ME] (rDEN2/4delta30[ME])

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Dengue Fever | Phase 1 | Status: COMPLETED